DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Buprenex (Buprenorphine Hydrochloride) - Summary

 
 



BUPRENEX SUMMARY

Buprenex (buprenorphine hydrochloride) is a narcotic under the Controlled Substances Act due to its chemical derivation from thebaine.

Buprenex is indicated for the relief of moderate to severe pain.


See all Buprenex indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Buprenex (Buprenorphine)

Researchers identify factors associated with stopping treatment for opioid dependence
Source: Alcohol / Addiction / Illegal Drugs News From Medical News Today [2017.01.09]
Individuals with opioid use disorder who are treated with buprenorphine, a commonly prescribed drug to treat addiction, are more likely to disengage from treatment programs if they are black or...

Suboxone Maker Pulls Pills in Favor of Film
Source: MedPage Today Product Alert [2012.09.25]
The buprenorphine-naloxone combination product (Suboxone) in sublingual tablet form will soon be pulled from the U.S. market because its child-resistant packaging isn't effective enough.

more news >>

Published Studies Related to Buprenex (Buprenorphine)

Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. [2014]
neonatal clinical outcomes... CONCLUSIONS: (1) Findings failed to support the existence of a dose-response

A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers. [2013]
IMPORTANCE: Although abuse of prescription opioids (POs) is a significant public health problem, few experimental studies have investigated the treatment needs of this growing population. OBJECTIVE: To evaluate, following brief stabilization with a combination of buprenorphine hydrochloride and naloxone hydrochloride dihydrate, the relative efficacy of 1-, 2-, and 4-week buprenorphine tapering regimens and subsequent naltrexone hydrochloride therapy in PO-dependent outpatients...

A randomised controlled trial of sublingual buprenorphine-naloxone film versus tablets in the management of opioid dependence. [2013]
(substance use, psychosocial function)... CONCLUSIONS: The study demonstrated dose equivalence and comparable clinical

Cocaine use reduction with buprenorphine (CURB): rationale, design, and methodology. [2013]
study... CONCLUSIONS: This research using 2 medications will demonstrate whether BUP,

Analgesia after feline ovariohysterectomy under midazolam-medetomidine-ketamine anaesthesia with buprenorphine or butorphanol, and carprofen or meloxicam: a prospective, randomised clinical trial. [2012]
One hundred female cats undergoing routine ovariohysterectomy under midazolam-medetomidine-ketamine anaesthesia were included in a blinded, randomised, prospective clinical study to compare postoperative analgesia produced by four analgesic drug combinations given preoperatively (n = 25 per group)...

more studies >>

Clinical Trials Related to Buprenex (Buprenorphine)

Buprenorphine for the Treatment of Neonatal Abstinence Syndrome [Completed]
Neonatal abstinence syndrome is a disease that affects children who were exposed to opioid drugs prior to birth. Commonly used treatments at present include morphine or tincture of opium. Buprenorphine is a drug used in adults to treat narcotic dependence, but has not been used for Neonatal Abstinence Syndrome. This trial is designed to see if the use of sublingual (under the tongue) buprenorphine is able to be used safely and easily in newborns with the neonatal abstinence syndrome. Secondary goals will be to see if treatment with buprenorphine is associated shorter stays in the hospital and fewer days of treatment than the use of standard therapy. Another secondary goal will be to understand buprenorphine concentration in the blood of babies treated with the drug (this is called "pharmacokinetics").

Preference for Subutex� (Buprenorphine) Versus Suboxone� (Buprenorphine/Naloxone) in Opioid Dependent Patients on Subutex� (Study P05094)(COMPLETED) [Completed]
This study is designed to determine if opioid dependent subjects who are already receiving Subutex prefer the Suboxone tablet over the Subutex tablet after switching from Subutex to Suboxone. Subjects who are selected to participate in this study will continue their prescribed dose of Subutex (buprenorphine 2 to 16 mg daily) for the first two days of the study (Day 1 and Day 2) then switch to and receive an equivalent dose of Suboxone® (buprenorphine 2 to 16 mg daily) for the last 3 days of the study (Day 3, Day 4 and Day 5). The Day 5 Visit will be the subject's last study visit. Upon completing the study, subjects will continue their pre-study prescribed dosage of Subutex®.

A Six-Month Randomized Controlled Trial (RCT) of Probuphine Safety and Efficacy in Opioid Addiction [Completed]
Probuphine (buprenorphine implant) is an implant placed just below the skin containing buprenorphine (BPN). BPN is an approved treatment for opioid dependence. This study will confirm the efficacy of Probuphine vs. placebo and compare Probuphine treatment verses treatment with sublingual buprenorphine in the treatment of patients with opioid dependence.

Disposition Effects of Cyclosporin on Buprenorphine [Recruiting]
The purpose of this study is to see how healthy volunteers bodies handle buprenorphine.

Buprenorphine Treatment for Opioid Dependence [Recruiting]
This is a randomized, open-label clinical trial with 200 Veteran opioid dependent men and women. Veterans will be randomized to one of two treatment groups: low dose range of buprenorphine (<8mg) vs. high dose range of buprenorphine (<16mg). During induction into buprenorphine, all participants will be started at a dose of 2mg, and this dose will be increased as needed for stabilization of opioid withdrawal symptoms, up to 8mg for the low dose group, and up to 16mg for the high dose group, within a 5 day period. Participants will be seen on a daily basis (excluding weekends) for the initial 5 day induction. At the end of the 12-week study, participants will either be referred to a buprenorphine clinic if they wish to continue this medication, or if they wish to be drug free, will undergo detoxification from buprenorphine for up to a 4-week period. Follow-up visits, scheduled at 1, 3, and 6 months after study completion, will evaluate the durability of treatment effects on drug use and psychosocial outcomes. Veterans will be recruited primarily through advertisement, but also through the clinical facilities at the VA and from other collaborators.

more trials >>


Page last updated: 2017-01-09

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015